We are live on ! Find out more

Filana Therapeutics

FLNA

Market cap $29.6M

0.6118 USD

-0.0237

3.73%

At close Updated Oct 26, 4:00 PM EDT

Pre-market

After hours

0.6040

-0.0078

1.27%

1 day

-3.73%

5 days

-8.96%

1 month

-28.29%

3 months

-32.05%

6 months

-60.78%

Year to date

-70.73%

1 year

-83.9%

5 years

-98.7%

10 years

-86.1%

About: Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Employees: 20

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company's management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York.

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).

Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigators Ongoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's investigational new drug (IND) application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy.

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein. “2026 has been a year of important progress and new beginnings for Filana Therapeutics.

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company's clinical development program evaluating simufilam in TSC-related epilepsy.

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

Cassava Sciences says US DOJ has closed investigation into company

Cassava Sciences said on Thursday the U.S. Department of Justice had ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam.

Cassava Sciences says US DOJ has closed investigation into company

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders.

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Cassava Announces Agreement to Settle Securities Class Action Litigation

AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austin Division (In re Cassava Sciences, Inc. Securities Litigation, No. 1:21-cv-00751-DAE) (the “Consolidated Securities Action”). This lawsuit was originally filed in 2021.

Cassava Announces Agreement to Settle Securities Class Action Litigation

See News Rankings

Price charts implemented using Lightweight Charts™